AstraZeneca has reportedly rejected a reported $106 billion buyout offer made by US peer Pfizer last Friday, claiming the bid “substantially” undervalued the company.
According to reports, Pfizer submitted its bid and UK-based AstraZeneca rejected it all in the same day. Should the companies eventually agree on a price tag, such …read more
Source: Global Competition Law Blogs